Non-anticoagulant HS

About TEGA Therapeutics

TEGA Therapeutics is a private, pre-clinical stage biotech leveraging proprietary glycoscience to engineer recombinant heparan sulfate (HS) as a therapeutic and reagent. The company has two main programs: developing recombinant heparin as a safer alternative to animal-sourced anticoagulants and creating enzyme replacement therapies for HS degradation disorders. While currently pre-revenue with a reagent sales channel, TEGA's technology addresses significant unmet needs in anticoagulation, virology (including COVID-19), and inflammatory lung diseases, positioning it in a high-value but technically challenging niche of glycobiology.

Therapeutic Areas